Botulinum toxin type A + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Glabellar Lines
Conditions
Moderate to Severe Glabellar Lines
Trial Timeline
Jan 1, 2015 → Aug 1, 2015
NCT ID
NCT02353871About Botulinum toxin type A + Placebo
Botulinum toxin type A + Placebo is a phase 3 stage product being developed by Ipsen for Moderate to Severe Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT02353871. Target conditions include Moderate to Severe Glabellar Lines.
What happened to similar drugs?
6 of 20 similar drugs in Moderate to Severe Glabellar Lines were approved
Approved (6) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03569098 | Phase 2 | Completed |
| NCT03598777 | Phase 2 | Terminated |
| NCT02493946 | Phase 3 | Completed |
| NCT02353871 | Phase 3 | Completed |
| NCT02321436 | Approved | Completed |
| NCT01753310 | Phase 3 | Completed |
| NCT01249417 | Phase 3 | Completed |
| NCT01357980 | Phase 2 | Completed |
| NCT01249404 | Phase 3 | Completed |
| NCT00578097 | Phase 2 | Terminated |
| NCT00257660 | Phase 3 | Completed |
| NCT00447876 | Phase 2/3 | Completed |
| NCT00216411 | Approved | Completed |
| NCT00234546 | Approved | Completed |
Competing Products
20 competing products in Moderate to Severe Glabellar Lines